| Literature DB >> 28152021 |
Kyung-Hee Kim1,2, Seung-Gu Yeo3, Byong Chul Yoo2, Jae Kyung Myung4.
Abstract
Calgranulin B is known to be involved in tumor development, but the underlying molecular mechanism is not clear. To gain insight into possible roles of calgranulin B, we screened for calgranulin B-interacting molecules in the SNU-484 gastric cancer and the SNU-81 colon cancer cells. Calgranulin B-interacting partners were identified by yeast two-hybrid and functional information was obtained by computational analysis. Most of the calgranulin B-interacting partners were involved in metabolic and cellular processes, and found to have molecular function of binding and catalytic activities. Interestingly, 46 molecules in the network of the calgranulin B-interacting proteins are known to be associated with cancer and FKBP2 was found to interact with calgranulin B in both SNU-484 and SNU-81 cells. Polyubiquitin-C encoded by UBC, which exhibited an interaction with calgranulin B, has been associated with various molecules of the extracellular space and plasma membrane identified in our screening, including Na-K-Cl cotransporter 1 and dystonin in SNU-484 cells, and ATPase subunit beta-1 in SNU-81 cells. Our data provide novel insight into the roles of calgranulin B of gastrointestinal cancer cells, and offer new clues suggesting calgranulin B acts as an effector molecule through which the cell can communicate with the tumor microenvironment via polyubiquitin-C.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28152021 PMCID: PMC5289589 DOI: 10.1371/journal.pone.0171232
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Overview of the experimental procedure.
A scheme of the experimental workflow used for identification and functional analysis of calgranulin B interacting molecules was illustrated.
Fig 2Yeast two-hybrid screening of calgranulin B-interacting partners.
Positive interactions were identified through growth in selective media with different levels of restrictiveness. Positive clones were isolated and sequenced from the SNU-484 human gastric cancer cell line (A), the SNU-81 human colon cancer cell line (B), and the HEK293 human kidney cell line (C).
List of identified significant genes interacting with calgranulin B.
| Cell line | ID | Description | Frame | Reporter expression | |||
|---|---|---|---|---|---|---|---|
| 3 | A-kinase-interacting protein 1 isoform b [Homo sapiens] | +1 | +++ | +++ | +++ | +++ | |
| 4 | PREDICTED: thioredoxin, mitochondrial isoform X1 [Homo sapiens] | +1 | +++ | +++ | +++ | - | |
| 7 | pyruvate dehydrogenase protein X component, mitochondrial isoform 2 [Homo sapiens] | +1 | +++ | +++ | +++ | +++ | |
| 9 | 60S ribosomal protein L18 isoform 1 [Homo sapiens] | +1 | ++ | ++ | ++ | + | |
| 11 | ribosomal protein L11, isoform CRA_a [Homo sapiens] | +1 | + | ++ | ++ | - | |
| 12 | A-kinase-interacting protein 1 isoform b [Homo sapiens] | +1 | +++ | +++ | +++ | +++ | |
| 28 | ran-binding protein 9 [Homo sapiens] | +1 | +++ | +++ | +++ | ++ | |
| 29 | NAG13 [Homo sapiens] | +1 | + | +++ | +++ | ++ | |
| 31 | afadin isoform X17 [Homo sapiens] | +1 | ++ | +++ | ++ | +++ | |
| 34 | peptidyl-prolyl cis-trans isomerase FKBP2 precursor [Homo sapiens] | +1 | ++ | +++ | +++ | ++ | |
| 35 | procollagen C-endopeptidase enhancer 1 precursor [Homo sapiens] | +1 | +++ | +++ | +++ | + | |
| 37 | ribosomal L1 domain-containing protein 1 [Homo sapiens] | +1 | + | +++ | +++ | ++ | |
| 39 | dystonin, isoform CRA_f [Homo sapiens] | +1 | + | ++ | ++ | - | |
| 50 | COMM domain-containing protein 1 [Homo sapiens] | +1 | ++ | ++ | ++ | - | |
| 1 | succinate dehydrogenase [ubiquinone] iron-sulfur subunit, mitochondrial precursor [Homo sapiens] | +1 | +++ | +++ | +++ | +++ | |
| 5 | probable tRNA pseudouridine synthase 1 [Homo sapiens] | +1 | + | ++ | ++ | - | |
| 6 | Homo sapiens chromosome 19, alternate assembly CHM1_1.1 | +1 | +++ | +++ | +++ | - | |
| 18 | NEDD4-like E3 ubiquitin-protein ligase WWP2 isoform WWP2-N [Homo sapiens] | +1 | ++ | ++ | ++ | - | |
| 24 | 60S ribosomal protein L39 [Homo sapiens] | +1 | +++ | +++ | +++ | +++ | |
| 46 | OCIA domain containing 2, isoform CRA_b [Homo sapiens] | +1 | +++ | +++ | +++ | +++ | |
| 49 | peptidyl-prolyl cis-trans isomerase FKBP2 precursor [Homo sapiens] | +1 | ++ | ++ | ++ | ++ | |
| 50 | OCIA domain-containing protein 2 isoform 2 [Homo sapiens] | +1 | +++ | +++ | +++ | +++ | |
| 52 | integrin beta-1-binding protein 1 isoform 1 [Homo sapiens] | +1 | ++ | + | + | - | |
| 57 | PREDICTED: lysophosphatidic acid phosphatase type 6 isoform X1 [Homo sapiens] | +1 | ++ | ++ | ++ | ++ | |
| 58 | fructose-bisphosphate aldolase C [Homo sapiens] | +1 | ++ | ++ | ++ | + | |
| 60 | sodium/potassium-transporting ATPase subunit beta-1 [Homo sapiens] | +1 | +++ | +++ | +++ | +++ | |
| 62 | signal peptidase complex subunit 2 [Homo sapiens] | +1 | +++ | +++ | +++ | +++ | |
| 1–2 | KIAA1109 protein | +1 | ++ | +++ | +++ | ++ | |
| 1–4 | KIAA1109 protein | +1 | ++ | +++ | +++ | ++ | |
| 1–6 | splicing factor, arginine/serine-rich 2, interacting protein, isoform CRA_b | +1 | +++ | +++ | +++ | - | |
| 1–8 | zinc finger protein 737 isoform X3 | +1 | +++ | +++ | +++ | +++ | |
| 2–1 | rho GDP-dissociation inhibitor 1 isoform a [Homo sapiens] | +1 | +++ | +++ | +++ | ++ | |
| 2–3 | DNA replication licensing factor MCM7 isoform 2 [Homo sapiens] | +1 | +++ | +++ | +++ | +++ | |
| 2–4 | DNA replication licensing factor MCM7 isoform 2 [Homo sapiens] | +1 | +++ | +++ | +++ | +++ | |
| 2–7 | AT-rich interactive domain-containing protein 2 isoform X1 | +1 | ++ | +++ | +++ | +++ | |
| 2–11 | differentially expressed in FDCP 8 homolog isoform 2 [Homo sapiens] | +1 | ++ | +++ | +++ | ++ | |
| 2–28 | DHX30 protein [Homo sapiens] | +1 | +++ | +++ | +++ | + | |
| 2–31 | reticulon-4 receptor precursor [Homo sapiens] | +1 | ++ | +++ | +++ | + | |
| 2–37 | 60S ribosomal protein L12 [Homo sapiens] | +1 | + | ++ | ++ | - | |
| 2–50 | NOMO3 protein, partial [Homo sapiens] | +1 | +++ | +++ | +++ | +++ | |
| 2–55 | ran-binding protein 10 isoform X1 [Homo sapiens] | +1 | +++ | +++ | +++ | +++ | |
| 2–57 | peroxiredoxin-6 [Homo sapiens] | +1 | ++ | ++ | ++ | + | |
| 2–59 | CEV14 [Homo sapiens] | +1 | ++ | +++ | +++ | ++ | |
| 2–60 | PREDICTED: COP9 signalosome complex subunit 1 isoform X13 [Homo sapiens] | +1 | ++ | ++ | ++ | - | |
| 2–62 | 60S ribosomal protein L12 [Homo sapiens] | +1 | ++ | ++ | ++ | ++ | |
| 2–65 | probable hydrolase PNKD isoform 3 precursor [Homo sapiens] | +1 | ++ | ++ | ++ | + | |
Fig 3Molecular function gene ontology (GO) terms overrepresented among the calgranulin B-interacting partners.
The distributions of the molecular functions represented by the calgranulin B-interacting molecules identified in SNU-484 (A), SNU-81 (B), and HEK293 (C) cells are shown.
Fig 5Cellular components associated with the calgranulin B-interacting molecules.
The calgranulin B-interacting molecules identified in SNU-484 (A), SNU-81 (B), and HEK293 (C) cells were categorized according to cellular component information.
Fig 4Biological processes overrepresented among the calgranulin B-interacting partners.
The distributions of the biological processes represented by the calgranulin B-interacting molecules identified in SNU-484 (A), SNU-81 (B), and HEK293 (C) cells are shown.
List of diseases and disorders associated with molecules identified in three cell lines.
| Cell line | Name | p-value | # molecules |
|---|---|---|---|
| Cardiovascular Disease | 6.45E-04–6.45E-04 | 1 | |
| Connective Tissue Disorders | 6.45E-04–6.45E-04 | 1 | |
| Dermatological Diseases and Conditions | 6.45E-04–6.45E-04 | 1 | |
| Developmental Disorder | 6.45E-04–6.45E-04 | 2 | |
| Hematological Disease | 1.35E-02–6.45E-04 | 2 | |
| Cancer | 4.91E-02–5.91E-04 | 5 | |
| Connective Tissue Disorders | 1.41E-02–5.91E-04 | 3 | |
| Developmental Disorder | 1.41E-02–5.91E-04 | 2 | |
| Gastrointestinal Disease | 3.49E-03–5.91E-04 | 2 | |
| Hereditary Disorder | 1.41E-02–5.91E-04 | 2 | |
| Cancer | 4.13E-02–8.60E-04 | 3 | |
| Developmental Disorder | 3.47E-02–8.60E-04 | 2 | |
| Hereditary Disorder | 4.13E-02–8.60E-04 | 2 | |
| Infectious Diseases | 8.60E-02–8.60E-04 | 1 | |
| Neurological Disease | 3.55E-02–8.60E-04 | 4 |
Fig 6PANTHER analysis of protein classes overrepresented among the calgranulin B-interacting partners.
Protein class distributions of the calgranulin B-interacting molecules identified in SNU-484 (A), SNU-81 (B), and HEK293 (C) cells are shown.
Fig 7PANTHER analysis of pathways overrepresented among the calgranulin B-interacting partners.
The pathway distributions of the calgranulin B-interacting molecules identified in SNU-484 (A), SNU-81 (B), and HEK293 (C) cells are shown.
Fig 8Network analysis and cancer associations of the calgranulin B-interacting molecules.
In the generated network, molecular interactions are shown by grey lines, the identified calgranulin B-interacting molecules are highlighted in purple, and molecules that have been associated with cancer are indicated by dotted blue lines.
Fig 9Communication of calgranulin B with extracellular environment via polyubiquitin-C(UBC) in SNU-484, SNU-81, and HEK293 cells.
Direct interactions with calgranulin B (S100A9) were predicted using STRING analysis, and are indicated by different colored lines: green, red, blue, black, purple, light blue, yellow, sky blue based on the types of evidence for associations.